JP2017522270A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017522270A5 JP2017522270A5 JP2016568653A JP2016568653A JP2017522270A5 JP 2017522270 A5 JP2017522270 A5 JP 2017522270A5 JP 2016568653 A JP2016568653 A JP 2016568653A JP 2016568653 A JP2016568653 A JP 2016568653A JP 2017522270 A5 JP2017522270 A5 JP 2017522270A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- biomarker
- level
- pharmaceutical composition
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000090 biomarker Substances 0.000 claims 37
- 150000001875 compounds Chemical class 0.000 claims 29
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 8
- -1 4-morpholin-4-ylmethylbenzyloxy Chemical group 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 5
- 101000599042 Homo sapiens Zinc finger protein Aiolos Proteins 0.000 claims 4
- 102100037798 Zinc finger protein Aiolos Human genes 0.000 claims 4
- 210000000265 leukocyte Anatomy 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 4
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical compound O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 claims 4
- 102000015367 CRBN Human genes 0.000 claims 3
- 102100037799 DNA-binding protein Ikaros Human genes 0.000 claims 3
- 101000599038 Homo sapiens DNA-binding protein Ikaros Proteins 0.000 claims 3
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims 3
- NSEVIVKAZHFLBF-UHFFFAOYSA-N piperidine-2,6-dione;hydrochloride Chemical compound Cl.O=C1CCCC(=O)N1 NSEVIVKAZHFLBF-UHFFFAOYSA-N 0.000 claims 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 239000002299 complementary DNA Substances 0.000 claims 2
- 230000002354 daily effect Effects 0.000 claims 2
- 210000003714 granulocyte Anatomy 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 210000001616 monocyte Anatomy 0.000 claims 2
- 210000005259 peripheral blood Anatomy 0.000 claims 2
- 239000011886 peripheral blood Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006820 Arthralgia Diseases 0.000 claims 1
- 206010008479 Chest Pain Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010013082 Discomfort Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 208000010201 Exanthema Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000000616 Hemoptysis Diseases 0.000 claims 1
- 208000004044 Hypesthesia Diseases 0.000 claims 1
- 108010013958 Ikaros Transcription Factor Proteins 0.000 claims 1
- 102000017182 Ikaros Transcription Factor Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 206010023232 Joint swelling Diseases 0.000 claims 1
- 206010024648 Livedo reticularis Diseases 0.000 claims 1
- 208000008771 Lymphadenopathy Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 206010031009 Oral pain Diseases 0.000 claims 1
- 206010034719 Personality change Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 206010047571 Visual impairment Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 230000003203 everyday effect Effects 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 208000034783 hypoesthesia Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000018555 lymphatic system disease Diseases 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 231100000862 numbness Toxicity 0.000 claims 1
- 208000035824 paresthesia Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 206010037844 rash Diseases 0.000 claims 1
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 1
- 230000033764 rhythmic process Effects 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 231100000046 skin rash Toxicity 0.000 claims 1
- 239000007787 solid Chemical group 0.000 claims 1
- 208000029257 vision disease Diseases 0.000 claims 1
- 230000004393 visual impairment Effects 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462000428P | 2014-05-19 | 2014-05-19 | |
| US62/000,428 | 2014-05-19 | ||
| US201462053626P | 2014-09-22 | 2014-09-22 | |
| US62/053,626 | 2014-09-22 | ||
| PCT/US2015/031345 WO2015179276A1 (en) | 2014-05-19 | 2015-05-18 | 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020080644A Division JP2020143083A (ja) | 2014-05-19 | 2020-04-30 | 全身性エリテマトーデスの治療のための３−（４−（（４−（モルホリノメチル−ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017522270A JP2017522270A (ja) | 2017-08-10 |
| JP2017522270A5 true JP2017522270A5 (enExample) | 2018-06-28 |
Family
ID=53268937
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016568653A Pending JP2017522270A (ja) | 2014-05-19 | 2015-05-18 | 全身性エリテマトーデスの治療のための３−（４−（（４−（モルホリノメチル−ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオン |
| JP2020080644A Pending JP2020143083A (ja) | 2014-05-19 | 2020-04-30 | 全身性エリテマトーデスの治療のための３−（４−（（４−（モルホリノメチル−ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオン |
| JP2021213603A Pending JP2022058443A (ja) | 2014-05-19 | 2021-12-28 | 全身性エリテマトーデスの治療のための３－（４－（（４－（モルホリノメチル－ベンジル）オキシ）－１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020080644A Pending JP2020143083A (ja) | 2014-05-19 | 2020-04-30 | 全身性エリテマトーデスの治療のための３−（４−（（４−（モルホリノメチル−ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオン |
| JP2021213603A Pending JP2022058443A (ja) | 2014-05-19 | 2021-12-28 | 全身性エリテマトーデスの治療のための３－（４－（（４－（モルホリノメチル－ベンジル）オキシ）－１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US10245266B2 (enExample) |
| EP (1) | EP3145513B1 (enExample) |
| JP (3) | JP2017522270A (enExample) |
| ES (1) | ES2969532T3 (enExample) |
| TW (2) | TWI745271B (enExample) |
| WO (1) | WO2015179276A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201501062SA (en) | 2010-02-11 | 2015-04-29 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| CN114939119A (zh) | 2012-08-09 | 2022-08-26 | 细胞基因公司 | 免疫相关和炎性疾病的治疗 |
| US20150038511A1 (en) | 2012-08-09 | 2015-02-05 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
| WO2014116573A1 (en) | 2013-01-22 | 2014-07-31 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
| JP2017522270A (ja) | 2014-05-19 | 2017-08-10 | セルジーン コーポレイション | 全身性エリテマトーデスの治療のための３−（４−（（４−（モルホリノメチル−ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオン |
| WO2018010142A1 (en) * | 2016-07-14 | 2018-01-18 | Shanghai Meton Pharmaceutical Co., Ltd | Iso-citrate dehydrogenase (idh) inhibitor |
| KR20210069642A (ko) | 2018-10-01 | 2021-06-11 | 셀진 코포레이션 | 암 치료를 위한 병용 요법 |
| TW202228705A (zh) * | 2020-10-02 | 2022-08-01 | 美商西建公司 | 治療全身性紅斑性狼瘡之方法及生物標記作為對療法之臨床敏感性之預測子之用途 |
| WO2024064646A1 (en) | 2022-09-20 | 2024-03-28 | Celgene Corporation | Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| TR200101504T2 (tr) | 1998-03-16 | 2002-06-21 | Celgene Corporation | 2-(2,6-dioksopiperidin-3-il)izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı. |
| US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
| GB0120441D0 (en) | 2001-08-22 | 2001-10-17 | Novartis Forschungsstiftung | Model of autoimmune disease and methods for identifying anti autoimmune disease disorders |
| US7173032B2 (en) | 2001-09-21 | 2007-02-06 | Reddy Us Therapeutics, Inc. | Methods and compositions of novel triazine compounds |
| US8088591B2 (en) | 2006-05-12 | 2012-01-03 | University Of Miami | Biomarkers for detection and diagnosis of head and neck squamous cell carcinoma |
| US20080045485A1 (en) | 2006-08-17 | 2008-02-21 | Peter Muir | Methods of diagnosing synovial disease in a mammal by detecting bacterial DNA in synovial tissues from dogs with inflammatory knee arthritis and degenerative anterior cruciate ligament rupture |
| NZ577111A (en) | 2006-12-15 | 2012-05-25 | Abbott Lab | Novel oxadiazole compounds |
| MX2009010082A (es) | 2007-03-20 | 2009-10-19 | Celgene Corp | Derivados y composiciones que comprenden isoindolina 4'-o-sustituida y metodos para utilizar la misma. |
| CN101680887B (zh) | 2007-03-30 | 2014-06-25 | 褚圣-贾斯汀公司 | 测定脊柱侧凸风险的方法 |
| JP5442185B2 (ja) | 2007-04-24 | 2014-03-12 | 日本メナード化粧品株式会社 | 感作性物質評価方法 |
| CA2720184C (en) | 2008-03-31 | 2017-07-18 | Boston Medical Center Corporation | Predictive marker for topoisomerase i inhibitors |
| CA2723648A1 (en) | 2008-04-10 | 2009-10-15 | Piyush Gupta | Methods for identification and use of agents targeting cancer stem cells |
| CA2744711C (en) | 2008-12-05 | 2017-06-27 | Abbott Laboratories | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| BRPI1011394A8 (pt) | 2009-04-18 | 2018-06-26 | Genentech Inc | método para avaliação de responsividade de linforma de células b ao tratamento com anticorpos anti-cd40 |
| SG10201501062SA (en) | 2010-02-11 | 2015-04-29 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| CN103237901B (zh) | 2010-03-01 | 2016-08-03 | 卡里斯生命科学瑞士控股有限责任公司 | 用于治疗诊断的生物标志物 |
| MX2012010367A (es) * | 2010-03-12 | 2012-11-23 | Celgene Corp | Metodos para el tratamiento de linfomas no hodgkin que usan lenalidomida y biomarcadores de genes y proteinas como un predictor. |
| CA2808417A1 (en) | 2010-08-18 | 2012-02-23 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers for disease |
| AU2012220872A1 (en) | 2011-02-22 | 2013-09-12 | Caris Life Sciences Switzerland Holdings Gmbh | Circulating biomarkers |
| US9730941B2 (en) * | 2012-06-07 | 2017-08-15 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the inhibition of Pin1 |
| ES2872967T3 (es) | 2012-06-29 | 2021-11-03 | Celgene Corp | Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS) |
| US9371568B2 (en) * | 2012-07-31 | 2016-06-21 | Novartis Ag | Markers associated with human double minute 2 inhibitors |
| CN114939119A (zh) | 2012-08-09 | 2022-08-26 | 细胞基因公司 | 免疫相关和炎性疾病的治疗 |
| US20150038511A1 (en) | 2012-08-09 | 2015-02-05 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
| US20140343058A1 (en) | 2012-08-09 | 2014-11-20 | Celgene Corporation | Treatment of systemic lupus erythematosus |
| UA117141C2 (uk) | 2013-10-08 | 2018-06-25 | Селджин Корпорейшн | Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
| JP2017522270A (ja) * | 2014-05-19 | 2017-08-10 | セルジーン コーポレイション | 全身性エリテマトーデスの治療のための３−（４−（（４−（モルホリノメチル−ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオン |
-
2015
- 2015-05-18 JP JP2016568653A patent/JP2017522270A/ja active Pending
- 2015-05-18 TW TW104115791A patent/TWI745271B/zh active
- 2015-05-18 WO PCT/US2015/031345 patent/WO2015179276A1/en not_active Ceased
- 2015-05-18 US US15/312,450 patent/US10245266B2/en active Active
- 2015-05-18 EP EP15725213.1A patent/EP3145513B1/en active Active
- 2015-05-18 ES ES15725213T patent/ES2969532T3/es active Active
- 2015-05-18 TW TW110125851A patent/TWI794885B/zh active
-
2019
- 2019-03-01 US US16/290,493 patent/US10596179B2/en active Active
-
2020
- 2020-02-25 US US16/801,000 patent/US10980812B2/en active Active
- 2020-04-30 JP JP2020080644A patent/JP2020143083A/ja active Pending
-
2021
- 2021-03-29 US US17/216,106 patent/US11660302B2/en active Active
- 2021-12-28 JP JP2021213603A patent/JP2022058443A/ja active Pending
-
2023
- 2023-05-03 US US18/142,973 patent/US20240041894A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017522270A5 (enExample) | ||
| JP2022058443A5 (enExample) | ||
| JP2020143083A5 (enExample) | ||
| Sun et al. | Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib | |
| Dhabhar | Effects of stress on immune function: the good, the bad, and the beautiful | |
| Khan et al. | Molecular and physiological manifestations and measurement of aging in humans | |
| Sawicki et al. | Microglia promote increased pain behavior through enhanced inflammation in the spinal cord during repeated social defeat stress | |
| Dimitrov et al. | Inflammation and exercise: Inhibition of monocytic intracellular TNF production by acute exercise via β2-adrenergic activation | |
| EP3974450A3 (en) | Biomarker | |
| JP2016512201A5 (enExample) | ||
| Amon et al. | Mastocytosis–an update | |
| Dong et al. | Oral treatment with SEW2871, a sphingosine-1-phosphate type 1 receptor agonist, ameliorates experimental colitis in interleukin-10 gene deficient mice | |
| JP2017522270A (ja) | 全身性エリテマトーデスの治療のための３−（４−（（４−（モルホリノメチル−ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオン | |
| Medina et al. | Ebi3 prevents Trypanosoma cruzi-induced myocarditis by dampening IFN-γ-driven inflammation | |
| Inal et al. | Fibromyalgia and nondipper circadian blood pressure variability | |
| Rombout‐Sestrienkova et al. | Course of iron parameters in HFE‐hemochromatosis patients during initial treatment with erythrocytapheresis compared to phlebotomy | |
| Aizman et al. | Therapeutic effect of farnesylthiosalicylic acid on adjuvant-induced arthritis through suppressed release of inflammatory cytokines | |
| Bakovic et al. | Changes in platelet size and spleen volume in response to selective and non‐selective Β‐adrenoceptor blockade in hypertensive patients | |
| Knopp et al. | Optic and auditory pathway dysfunction in demyelinating neuropathies | |
| JP4842964B2 (ja) | 炎症用生体マーカー | |
| JP2015513901A5 (enExample) | ||
| US20190032146A1 (en) | Compositions and methods for predicting response and resistance to cdk4/6 inhibition | |
| Chen et al. | Celecoxib alleviates oxaliplatin-induced hyperalgesia through inhibition of spinal ERK1/2 signaling | |
| BR112012030051A2 (pt) | índice de saúde oral | |
| Roy et al. | Gait speed is a biomarker of cancer-associated cachexia decline and recovery |